ART reports first human use of its next-generation bioresorbable stent

PARIS, July 16, 2012—Arterial Remodeling Technologies (“ART”) reported today that the Company has achieved a medical milestone with its “ARTDIVA” (Arterial Remodeling Transient DIsmantling Vascular Angioplasty) clinical trial: the successful First-in-Human implantation of its novel biodegradable stent into an 61-year-old male who was suffering from a blocked coronary artery and needed a percutaneous coronary intervention (PCI). ART’s next-generation bioresorbable stent is designed to promote positive arterial remodeling and then bioresorb (i.e., ‘disappear’) in approximately 18 months.

 

ART-News 120716